Show simple item record

dc.contributor.authorKlevmoen, Marianne
dc.contributor.authorBogsrud, Martin Prøven
dc.contributor.authorRetterstøl, Kjetil
dc.contributor.authorSvilaas, Tone
dc.contributor.authorVesterbekkmo, Elisabeth Kleivhaug
dc.contributor.authorHovland, Anders
dc.contributor.authorBerge, Christ
dc.contributor.authorvan Lennep, Jeanine Roeters
dc.contributor.authorHolven, Kirsten Bjørklund
dc.date.accessioned2022-01-07T13:09:05Z
dc.date.available2022-01-07T13:09:05Z
dc.date.issued2021-09-03
dc.description.abstractBackground and aims Women with heterozygous familial hypercholesterolemia (FH) are recommended to initiate statin treatment at the same age as men (from 8 to 10 years of age). However, statins are contraindicated when pregnancy is planned, during pregnancy and breastfeeding. The aim of the study was to determine the duration of pregnancy-related off-statin periods and breastfeeding in FH women. Methods A cross-sectional study using an anonymous online self-administered questionnaire was conducted. Women with FH were recruited through Lipid Clinics in Norway and Netherlands and national FH patient organizations. Results 102 women with FH (n = 70 Norwegian and n = 32 Dutch) were included in the analysis. Total length of pregnancy-related off-statin periods was estimated for 80 women where data were available, and was median (min-max) 2.3 (0–14.2) years. Lost statin treatment time was estimated for 67 women where data were available, and was median (min-max) 18 (0–100)% at mean (SD) age of 31 (4.3) years at last pregnancy. More women breastfed in Norway (83%) and for longer time [8.5 [1-42] months] compared to the Netherlands [63%, p = 0.03; 3.6 (0–14) months, p < 0.001]. Eighty-six percent of the women reported need for more information on pregnancy and breastfeeding in relation to FH. Conclusions Young FH women lose years of treatment when discontinuing statins in relation to pregnancy and breastfeeding periods and should be closely followed up to minimize the duration of these off-statin periods. Whether these periods of interrupted treatment increase the cardiovascular risk in FH women needs to be further elucidated.en_US
dc.identifier.citationKlevmoen M, Bogsrud, Retterstøl, Svilaas T, Vesterbekkmo EK, Hovland, Berge, van Lennep, Holven. Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia. Atherosclerosis. 2021;335:8-15en_US
dc.identifier.cristinIDFRIDAID 1938155
dc.identifier.doi10.1016/j.atherosclerosis.2021.09.003
dc.identifier.issn0021-9150
dc.identifier.issn1879-1484
dc.identifier.urihttps://hdl.handle.net/10037/23629
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalAtherosclerosis
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.titleLoss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemiaen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record